サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1564904

全身麻酔薬の世界市場

General Anesthesia Drugs

出版日
ページ情報
英文 193 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.96円
全身麻酔薬の世界市場
出版日: 2024年10月04日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 193 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

全身麻酔薬の世界市場は2030年までに98億米ドルに達する見込み

2023年に78億米ドルと推定される全身麻酔薬の世界市場は、分析期間2023-2030年にCAGR 3.2%で成長し、2030年には98億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるプロポフォールは、CAGR 3.1％を記録し、分析期間終了時には25億米ドルに達すると予測されます。セボフルランセグメントの成長率は、分析期間中CAGR 3.2％と推定されます。

米国市場は21億米ドルと推定、中国はCAGR 4.8％で成長予測

米国の全身麻酔薬市場は2023年に21億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに19億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは4.8%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.2%と2.6%と予測されています。欧州では、ドイツがCAGR 2.5%で成長すると予測されています。

世界の全身麻酔薬市場- 主要動向と促進要因のまとめ

なぜ全身麻酔薬は現代の外科手術や医療処置に不可欠なのか？

全身麻酔薬は現代の外科手術や医療処置において非常に重要であり、患者は複雑で侵襲的な手術を痛みや不快感、意識なしに受けることができます。しかし、なぜ今日、これらの薬剤が必要不可欠なのでしょうか？全身麻酔は、可逆的な意識喪失、鎮痛、筋弛緩、健忘状態を引き起こし、患者に苦痛や身体的危害を与えることなく、外科医が複雑な手術を行うことを可能にします。日常的な手術から救命手術に至るまで、全身麻酔によって患者は術中ずっと意識がなく、痛みもない状態を保つことができ、現代医学の成功と安全に貢献しています。

これらの薬剤は、心臓バイパス手術、臓器移植、整形外科手術などの大手術や、大腸内視鏡検査や生検など、患者が長時間じっとしている必要がある診断的処置など、さまざまな医療現場で使用されています。麻酔科医は、年齢、体重、健康状態、手術の内容などを考慮し、安全で効果的な鎮静のための薬剤の適切なバランスを確保しながら、患者さん一人ひとりに合わせた全身麻酔の投与を行います。意識、痛み、身体機能をコントロールする能力は、手術の精度を高めるために不可欠であり、ヘルスケア専門家は患者の動きや不快感を心配することなく、目の前の作業に完全に集中することができます。

技術の進歩は、全身麻酔薬の安全性と精度をどのように向上させているか？

技術的進歩は、全身麻酔薬の安全性、精度、管理全般を大幅に向上させ、より良い患者転帰を保証し、麻酔に関連するリスクを軽減しています。最もインパクトのある進歩のひとつは、麻酔科医が手術中の心拍数、酸素濃度、血圧、脳活動などの患者のバイタルサインを綿密に追跡できる高度なモニタリングシステムのイントロダクションです。これらのリアルタイム・モニタリング・システムは、患者の麻酔に対する反応に関する重要なフィードバックを提供し、ヘルスケア提供者が理想的な麻酔深度を維持するために薬剤の投与量をリアルタイムで調整することを可能にします。この技術は、手術中の意識障害や副作用につながる麻酔の過不足といった合併症を防ぐのに役立ちます。

もうひとつの重要な進歩は、鎮静レベルをよりコントロールし、回復時間を短縮する短時間作用型の麻酔薬の開発です。プロポフォール、セボフルラン、デスフルランなどの最新の麻酔薬は、麻酔の導入と解除を迅速に行えるため、広く使用されるようになった。これらの麻酔薬は、麻酔時間のコントロールがより正確に行えるため、回復が長引いたり、吐き気、嘔吐、認知障害などの術後合併症のリスクが軽減されます。回復時間の短縮は、患者が術後速やかに意識と安定を取り戻す必要のある外来手術において特に有益です。

薬理ゲノミクス（遺伝子が薬物に対する反応にどのような影響を与えるかを研究する学問）の台頭も、麻酔の進化に一役買っています。麻酔科医は現在、遺伝子データを用いて、患者が特定の麻酔薬をどのように代謝するかを予測することができます。これにより、副作用の可能性が減少し、各患者が、その患者固有の遺伝的体質に合わせた最も効果的で安全な麻酔計画を受けられるようになります。さらに、標的制御注入（TCI）ポンプのようなドラッグデリバリーシステムの進歩は、麻酔薬の投与速度をより正確に制御し、精度を向上させ、過剰投与や合併症のリスクを低減します。

モニタリング、薬剤処方、遺伝的洞察、デリバリー・システムにおけるこれらの進歩により、全身麻酔の投与は、より安全で効率的になり、個々の患者のニーズにより適合するようになった。

なぜ全身麻酔薬が手術中の患者の安全性と快適性に重要なのでしょうか？

全身麻酔薬は、完全な鎮痛、意識消失、筋弛緩を提供するため、手術中の患者の安全性と快適性を確保するための基本です。全身麻酔の最も重要な役割のひとつは、侵襲的な処置中の痛みを防ぐことです。これらの薬剤がなければ、患者は耐え難い痛みを経験することになり、手術中の外傷、ショック、重大な生理的ストレスにつながる可能性があります。全身麻酔薬は、中枢神経系が痛みの信号を処理する能力を阻害することで痛みの知覚を遮断し、患者が手術中痛みを感じないようにします。

さらに、全身麻酔は意識のない状態を誘導するため、外科医は患者に苦痛を与えることなく、複雑で長時間の手術を行うことができます。全身麻酔に使用される薬剤には筋弛緩剤も含まれており、整形外科手術や神経外科手術のような、正確さと不動性が要求される手術では特に重要です。麻酔薬は患者の筋肉を弛緩させることで、外科医の作業を妨げる不随意運動を防ぎ、手術の安全性と成功率を高める。

術後のケアも全身麻酔によって改善されます。通常、麻酔薬には健忘を引き起こす薬剤が含まれているため、患者は手術やそれに伴う不快感の記憶がないです。このように手術中に意識がなくなることで、侵襲的な処置に伴う心理的外傷のリスクを軽減することができます。さらに、全身麻酔は完全な鎮静を確保することで、大手術中に損なわれる可能性のある心血管系や呼吸器系などの身体への生理的ストレスを軽減します。このようにコントロールされた環境は、特に持病のある患者やリスクの高い手術を受ける患者の安全にとって不可欠です。

全体として、全身麻酔の役割は、患者が快適で痛みを感じないようにするだけでなく、手術を安全かつ効果的に行うことができる安定した生理学的環境を作り出すことです。全身麻酔は現代の外科医療に不可欠な要素であり、より高い精度、より少ない合併症、より良い患者の転帰を可能にします。

全身麻酔薬市場の成長を促進する要因は？

全身麻酔薬市場は、手術件数の増加、薬剤製剤の進歩、患者の安全性と回復への関心の高まりなど、いくつかの重要な要因によって大きな成長を遂げています。まず、選択手術、緊急手術、外来手術を含む外科手術の世界の増加は、麻酔薬市場の主要な促進要因です。特に発展途上地域でヘルスケア・インフラが改善するにつれ、外科治療へのアクセスが拡大し、麻酔サービスの需要増につながっています。加えて、人口の高齢化や心血管疾患、がん、整形外科疾患などの慢性疾患の罹患率の増加が手術件数の増加に寄与しており、全身麻酔薬のニーズをさらに押し上げています。

第二に、麻酔薬製剤の進歩が市場成長の原動力となっています。プロポフォール、セボフルラン、レミフェンタニルなどの新しい麻酔薬の開発により、全身麻酔がより安全で効率的になり、患者の忍容性も向上しました。これらの薬剤は、速やかな麻酔開始と回復、副作用の軽減、鎮静深度のコントロールが可能であり、幅広い外科手術に理想的です。より短時間で作用する麻酔薬を必要とする低侵襲手術への嗜好の高まりも、患者の早期回復と入院期間の短縮を可能にする先進的な全身麻酔薬の需要に寄与しています。

第三に、患者の安全性と回復プロトコルの強化が重視されるようになり、全身麻酔薬市場を押し上げています。ヘルスケアプロバイダーは、術後合併症の軽減と、患者に合わせた麻酔レジメンの使用による転帰の改善に注力しています。手術後の回復促進（ERAS：Enhanced Recovery After Surgery）プロトコルは、手術による身体的ストレスを最小限に抑えることを目的としており、多くの場合、回復を早め、術後の吐き気、嘔吐、認知機能障害のリスクを低減する最新の麻酔薬が取り入れられています。病院や手術センターが患者ケアのベストプラクティスを採用する中、こうした高度な麻酔ソリューションへの需要が市場成長の原動力となっています。

さらに、外来患者や外来手術センターの拡大が全身麻酔薬の需要を促進しています。患者が即日退院する外来での手術が増えるにつれ、回復が早く副作用の少ない麻酔薬へのニーズが高まっています。白内障手術、内視鏡手術、美容整形手術などの外来手術では、患者がすぐに意識を取り戻し、長期入院の必要なく回復できるような短時間作用型の麻酔薬が使用されています。

最後に、ヘルスケア支出の増加と、標的制御注入（TCI）装置や高度なモニタリング技術などの麻酔投与システムの技術進歩も、市場成長に寄与しています。これらの技術革新は、より安全で正確な麻酔薬投与を保証し、患者の安全性をさらに高め、より新しく効果的な麻酔薬への需要を促進しています。

結論として、全身麻酔薬市場の成長は、手術件数の増加、麻酔薬製剤の進歩、患者の安全重視、外来外科治療の拡大によってもたらされます。ヘルスケアプロバイダーが手術結果の改善と回復時間の短縮を優先し続ける中、高品質な全身麻酔薬への需要が高まり、この不可欠な市場の継続的な拡大が見込まれます。

調査対象企業の例（注目の43社）

  • Abbott Laboratories
  • AstraZeneca PLC
  • Baxter International, Inc.
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche AG
  • Fresenius SE & Co. KGaA
  • Hikma Pharmaceuticals PLC
  • Hospira, Inc.
  • Novartis AG
  • Pfizer, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP12157

Global General Anesthesia Drugs Market to Reach US$9.8 Billion by 2030

The global market for General Anesthesia Drugs estimated at US$7.8 Billion in the year 2023, is expected to reach US$9.8 Billion by 2030, growing at a CAGR of 3.2% over the analysis period 2023-2030. Propofol, one of the segments analyzed in the report, is expected to record a 3.1% CAGR and reach US$2.5 Billion by the end of the analysis period. Growth in the Sevoflurane segment is estimated at 3.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.1 Billion While China is Forecast to Grow at 4.8% CAGR

The General Anesthesia Drugs market in the U.S. is estimated at US$2.1 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.9 Billion by the year 2030 trailing a CAGR of 4.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.2% and 2.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.5% CAGR.

Global General Anesthesia Drugs Market - Key Trends and Drivers Summarized

Why Are General Anesthesia Drugs Essential in Modern Surgery and Medical Procedures?

General anesthesia drugs are critical in modern surgery and medical procedures, allowing patients to undergo complex and often invasive operations without pain, discomfort, or awareness. But why are these drugs so essential today? General anesthesia induces a reversible state of unconsciousness, pain relief, muscle relaxation, and amnesia, making it possible for surgeons to perform intricate procedures without causing distress or physical harm to the patient. From routine surgeries to life-saving operations, general anesthesia ensures that patients remain unaware and pain-free throughout the procedure, contributing to the success and safety of modern medicine.

These drugs are used in a wide variety of medical settings, including major surgeries like heart bypass, organ transplants, and orthopedic operations, as well as in diagnostic procedures such as colonoscopies or biopsies that require patients to remain still for extended periods. Anesthesiologists tailor the administration of general anesthesia to each patient, taking into account factors like age, weight, health conditions, and the nature of the surgery to ensure the correct balance of drugs for safe and effective sedation. The ability to control consciousness, pain, and bodily functions is vital for surgical precision, allowing healthcare professionals to focus entirely on the task at hand without concerns over patient movement or discomfort.

How Are Technological Advancements Improving the Safety and Precision of General Anesthesia Drugs?

Technological advancements are significantly enhancing the safety, precision, and overall administration of general anesthesia drugs, ensuring better patient outcomes and reducing the risks associated with anesthesia. One of the most impactful developments is the introduction of advanced monitoring systems that allow anesthesiologists to closely track a patient’s vital signs, including heart rate, oxygen levels, blood pressure, and brain activity during surgery. These real-time monitoring systems provide critical feedback on how the patient is responding to the anesthesia, enabling healthcare providers to adjust drug dosages in real time to maintain the ideal depth of anesthesia. This technology helps prevent complications like under- or over-sedation, which can lead to awareness during surgery or adverse side effects.

Another important advancement is the development of shorter-acting anesthetic agents that offer greater control over sedation levels and quicker recovery times. Modern anesthetics such as propofol, sevoflurane, and desflurane have become widely used because they allow for rapid induction and emergence from anesthesia. These agents provide greater precision in controlling the duration of anesthesia, reducing the risks of prolonged recovery and post-operative complications like nausea, vomiting, or cognitive impairment. Faster recovery times are especially beneficial in outpatient surgeries, where patients need to regain consciousness and stability quickly after a procedure.

The rise of pharmacogenomics—the study of how genes affect a person’s response to drugs—also plays a role in the evolution of anesthesia. Anesthesiologists can now use genetic data to predict how a patient will metabolize specific anesthesia drugs, allowing for more personalized dosing strategies. This reduces the likelihood of adverse reactions and ensures that each patient receives the most effective and safest anesthetic plan tailored to their unique genetic makeup. Additionally, advancements in drug delivery systems, such as target-controlled infusion (TCI) pumps, offer more precise control over the rate at which anesthesia drugs are administered, improving accuracy and reducing the risk of overdose or complications.

With these advancements in monitoring, drug formulations, genetic insight, and delivery systems, the administration of general anesthesia has become safer, more efficient, and better tailored to the needs of individual patients, greatly improving the overall quality of care.

Why Are General Anesthesia Drugs Crucial for Patient Safety and Comfort During Surgery?

General anesthesia drugs are fundamental to ensuring patient safety and comfort during surgery, as they provide complete pain relief, unconsciousness, and muscle relaxation. One of the most important roles of general anesthesia is to prevent pain during invasive procedures. Without these drugs, patients would experience unbearable pain, which could lead to trauma, shock, and significant physiological stress during surgery. General anesthetics block the perception of pain by inhibiting the central nervous system’s ability to process pain signals, ensuring that patients remain pain-free throughout the procedure.

Additionally, general anesthesia induces a state of unconsciousness, allowing surgeons to perform complex and lengthy surgeries without causing distress to the patient. The drugs used in general anesthesia also include muscle relaxants, which are particularly important in surgeries requiring precision and immobility, such as orthopedic or neurosurgical procedures. By relaxing the patient’s muscles, anesthetics prevent involuntary movements that could interfere with the surgeon’s work, enhancing the safety and success of the operation.

Post-operative care is also improved by general anesthesia, as the drugs typically include agents that cause amnesia, meaning patients have no recollection of the surgery or the discomfort that might have been involved. This lack of awareness during surgery helps reduce the risk of psychological trauma associated with invasive procedures. Moreover, by ensuring complete sedation, general anesthesia reduces the physiological stress on the body, including the cardiovascular and respiratory systems, which could otherwise be compromised during major surgery. This controlled environment is essential for patient safety, especially for those with pre-existing medical conditions or undergoing high-risk surgeries.

Overall, the role of general anesthesia is not only to ensure that patients are comfortable and pain-free but also to create a stable physiological environment where the surgery can be performed safely and effectively. It is a vital component of modern surgical care, allowing for greater precision, fewer complications, and better patient outcomes.

What Factors Are Driving the Growth of the General Anesthesia Drugs Market?

The general anesthesia drugs market is experiencing significant growth, driven by several key factors, including the rising number of surgical procedures, advancements in drug formulations, and an increasing focus on patient safety and recovery. First, the global rise in surgical procedures, including elective, emergency, and outpatient surgeries, is a major driver of the anesthesia drugs market. As healthcare infrastructure improves, particularly in developing regions, access to surgical care is expanding, leading to an increased demand for anesthesia services. Additionally, the aging population and higher incidence of chronic diseases such as cardiovascular issues, cancer, and orthopedic problems are contributing to the growth of surgeries, further boosting the need for general anesthesia drugs.

Second, advancements in anesthetic drug formulations are driving market growth. The development of newer anesthetic agents, such as propofol, sevoflurane, and remifentanil, has made general anesthesia safer, more efficient, and better tolerated by patients. These drugs offer rapid onset and recovery, reduced side effects, and better control over sedation depth, making them ideal for a wide range of surgical procedures. The increasing preference for minimally invasive surgeries, which require shorter-acting anesthetics, is also contributing to the demand for advanced general anesthesia drugs that allow for quicker patient recovery and shorter hospital stays.

Third, the growing emphasis on patient safety and enhanced recovery protocols is boosting the market for general anesthesia drugs. Healthcare providers are focusing on reducing post-operative complications and improving patient outcomes through the use of tailored anesthesia regimens. Enhanced Recovery After Surgery (ERAS) protocols, which aim to minimize the physical stress of surgery, often incorporate modern anesthetic agents that facilitate quicker recovery and reduce the risk of post-operative nausea, vomiting, and cognitive dysfunction. The demand for these advanced anesthesia solutions is driving market growth as hospitals and surgical centers adopt best practices in patient care.

Additionally, the expansion of outpatient and ambulatory surgery centers is fueling the demand for general anesthesia drugs. As more surgeries shift to outpatient settings, where patients are discharged the same day, there is a growing need for anesthesia drugs that offer rapid recovery times and minimal side effects. Outpatient procedures such as cataract surgeries, endoscopies, and cosmetic surgeries rely on short-acting anesthetics that allow patients to regain consciousness quickly and recover without the need for extended hospitalization.

Lastly, rising healthcare spending and technological advancements in anesthesia delivery systems, such as target-controlled infusion (TCI) devices and advanced monitoring technologies, are also contributing to market growth. These innovations ensure safer, more precise administration of anesthesia drugs, further enhancing patient safety and driving demand for newer, more effective anesthetic agents.

In conclusion, the growth of the general anesthesia drugs market is driven by the increasing number of surgeries, advancements in anesthetic drug formulations, a focus on patient safety, and the expansion of outpatient surgical care. As healthcare providers continue to prioritize improved surgical outcomes and faster recovery times, the demand for high-quality general anesthesia drugs is expected to rise, ensuring the continued expansion of this essential market.

Select Competitors (Total 43 Featured) -

  • Abbott Laboratories
  • AstraZeneca PLC
  • Baxter International, Inc.
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche AG
  • Fresenius SE & Co. KGaA
  • Hikma Pharmaceuticals PLC
  • Hospira, Inc.
  • Novartis AG
  • Pfizer, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • General Anesthesia Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Number of Surgical Procedures Globally Drives Demand for General Anesthesia Drugs
    • Rising Prevalence of Chronic Diseases Necessitates More Complex Surgeries
    • Growing Geriatric Population and the Increasing Need for Surgical Interventions
    • Development of Ultra-Short Acting Anesthetics Improves Patient Recovery Time
    • Expanding Applications in Veterinary Surgeries Propel Market Expansion
    • Advances in Monitoring Technologies for Anesthesia Administration
    • Expansion of Ambulatory Surgery Centers Boosts Short-acting Anesthetic Use
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World General Anesthesia Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for General Anesthesia Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for General Anesthesia Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for General Anesthesia Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Propofol by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Propofol by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Propofol by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Sevoflurane by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Sevoflurane by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Sevoflurane by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Remifentanil by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Remifentanil by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Remifentanil by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Dexmedetomidine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Dexmedetomidine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Dexmedetomidine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Desflurane by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Desflurane by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Desflurane by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Isoflurane by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Isoflurane by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Isoflurane by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Midazolam by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Midazolam by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Midazolam by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Other Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Injection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Injection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Injection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Inhalation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Inhalation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: World 16-Year Perspective for Inhalation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • General Anesthesia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: USA 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: USA 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
  • JAPAN
    • General Anesthesia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 47: Japan Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Japan 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
  • CHINA
    • General Anesthesia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 53: China Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: China Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: China 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: China Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: China 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
  • EUROPE
    • General Anesthesia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 59: Europe Recent Past, Current & Future Analysis for General Anesthesia Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for General Anesthesia Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for General Anesthesia Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Europe 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
    • TABLE 65: Europe Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Europe 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
  • FRANCE
    • General Anesthesia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 68: France Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: France Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: France 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
    • TABLE 71: France Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: France Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: France 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
  • GERMANY
    • General Anesthesia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 74: Germany Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Germany 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
    • TABLE 77: Germany Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Germany Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Germany 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 80: Italy Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Italy 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
    • TABLE 83: Italy Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Italy Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Italy 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • General Anesthesia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 86: UK Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: UK 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
    • TABLE 89: UK Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: UK Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: UK 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 92: Spain Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Spain Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Spain 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
    • TABLE 95: Spain Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Spain Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Spain 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 98: Russia Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Russia Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Russia 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
    • TABLE 101: Russia Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Russia Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Russia 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Rest of Europe Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Rest of Europe 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
    • TABLE 107: Rest of Europe Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Rest of Europe Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Rest of Europe 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • General Anesthesia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for General Anesthesia Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for General Anesthesia Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for General Anesthesia Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Asia-Pacific 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
    • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Asia-Pacific Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Asia-Pacific 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • General Anesthesia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 119: Australia Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Australia Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Australia 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
    • TABLE 122: Australia Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Australia Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: Australia 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
  • INDIA
    • General Anesthesia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 125: India Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: India Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: India 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
    • TABLE 128: India Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: India Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: India 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 131: South Korea Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: South Korea Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: South Korea 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
    • TABLE 134: South Korea Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: South Korea Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: South Korea 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Rest of Asia-Pacific Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Rest of Asia-Pacific 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
    • TABLE 140: Rest of Asia-Pacific Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Rest of Asia-Pacific Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Rest of Asia-Pacific 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • General Anesthesia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for General Anesthesia Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for General Anesthesia Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for General Anesthesia Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Latin America 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
    • TABLE 149: Latin America Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Latin America Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Latin America 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 152: Argentina Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Argentina Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Argentina 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
    • TABLE 155: Argentina Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Argentina Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Argentina 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 158: Brazil Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Brazil Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Brazil 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
    • TABLE 161: Brazil Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Brazil Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Brazil 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 164: Mexico Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Mexico Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Mexico 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
    • TABLE 167: Mexico Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Mexico Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Mexico 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Rest of Latin America Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Rest of Latin America 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
    • TABLE 173: Rest of Latin America Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Rest of Latin America Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Rest of Latin America 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • General Anesthesia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for General Anesthesia Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for General Anesthesia Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for General Anesthesia Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Middle East 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
    • TABLE 182: Middle East Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Middle East Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Middle East 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 185: Iran Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Iran Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Iran 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
    • TABLE 188: Iran Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Iran Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Iran 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 191: Israel Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Israel Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Israel 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
    • TABLE 194: Israel Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Israel Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Israel 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Saudi Arabia Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Saudi Arabia 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
    • TABLE 200: Saudi Arabia Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Saudi Arabia Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Saudi Arabia 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 203: UAE Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: UAE Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: UAE 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
    • TABLE 206: UAE Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: UAE Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: UAE 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Rest of Middle East Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Rest of Middle East 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
    • TABLE 212: Rest of Middle East Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Rest of Middle East Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Rest of Middle East 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030
  • AFRICA
    • General Anesthesia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 215: Africa Recent Past, Current & Future Analysis for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Africa Historic Review for General Anesthesia Drugs by Drugs - Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 217: Africa 16-Year Perspective for General Anesthesia Drugs by Drugs - Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Remifentanil, Dexmedetomidine, Desflurane, Isoflurane, Midazolam and Other Drugs for the Years 2014, 2024 & 2030
    • TABLE 218: Africa Recent Past, Current & Future Analysis for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Africa Historic Review for General Anesthesia Drugs by Route Of Administration - Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 220: Africa 16-Year Perspective for General Anesthesia Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injection and Inhalation for the Years 2014, 2024 & 2030

IV. COMPETITION